Keynote Presentation on our Technologies

>>Watch the Keynote Presentation on our technologies

The Technologies of Regulon and an Introduction to the drug delivery process presented by our founder Dr. Teni Boulikas

Breakthrough in Oncology

One of the challenges in oncology (cancer therapy) is the introduction and delivery of the drug into the patient's body. Our patented liposomal technology delivers the leading anti-cancer drug preferentially to the tumor -without damaging surrounding healthy cells.

LipoPlatin™ - Liposomally encapsulated cis-platin has been formulated to perfection, treating only the tumor cells with minimized harm to the rest of the human body; while targeting and destroying the primary tumor as well as aggressively intervening with the metastatic sites.

>> What are Liposomes ?
>> What is Cis-Platin ?
>> What is LipoPlatin™ ?

CSS Template

Tumor Cells Targeted: Our Liposome (top) fusing with a tumor cell membrane

and injecting drug into tumor cell

>> Watch the presentation on tumor targeting

>> Subscribe to the REGULON RSS feed

Our Company Profile

We are a small-medium enterprise based in Mountain View, California USA, and Research Headquarters in Athens, Greece.

In 1999 Regulon, Inc. was established and today holds 20 Employees including a full research and oncology team. We are internationally recognized for our acheivment in drastic innovation in cancer medicine.

Our primary products are:

Liposomally encapsulated cis-platin, LipoPlatin™

Liposomally encapsulated oxaliplatin, LipOxal™

Featured Research Projects

Gene Therapy Against Morquio Syndrome.

New proprietary technique utilizing Gene Therapy to restore missing enzymes to victims living with mucopolysaccharidosis (Morquio syndrome) both types A and B.

EMEA Orphan Drug Status

Sept 14th, 2009 [Press Release]

On 8 June 2007, orphan designation (EU/3/07/451) was granted by the European Commission to Regulon AE, Greece, for cisplatin (liposomal) for the treatment of pancreatic cancer.

>> Download Full Document

Lipoplatin as a Trojan Horse for Cancer

Sept 17th, 2009 [Limited Press Release]

Evidence that Lipoplatin™ nanoparticles fuse with, and enter also by phagocytosis through, the cell membrane.